Skip to content

Moderna teams up with Chiesi Group in pulmonary arterial hypertension

September 16, 2020

Moderna (NASDAQ:MRNA) will collaborate with Italian healthcare research group Chiesi Farmaceutici S.p.A. to discover and develop mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH), a rare disorder characterized by high blood pressure in the arteries of the lungs with concomitant right heart failure.

Under the terms of the agreement, Moderna will lead discovery while Chiesi Group will lead development and global commercialization. It will fund all expenses related to the partnership.

Moderna will receive $25M upfront, up to $400M in milestones and tiered double-digit royalties on net sales.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: